| [1] |
中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版). 中华肝脏病杂志,2017,25:886-895.
|
| [2] |
Wang FS,Fan JG,Zhang Z,et al. The global burden of liver disease:The major impact of China. Hepatology, 2014,60:2099-2108.
|
| [3] |
中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版). 肝脏,2015,20:915-932.
|
| [4] |
Lim YS,Han S,Heo NY,et al. Mortality,liver transplantation,and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroen-terology,2014,147:152-161.
|
| [5] |
Pollicino T,Cacciola I,Saffioti F,et al. Hepatitis B virus PreS/S gene variants:pathobiology and clinical implications. J Hepatol,2014,61:408-417.
|
| [6] |
Salpini R,Surdo M,Warner N,et al. Novel HBsAg mutations correlate with hepatocellular carcinoma,hamper HBsAg secretion and promote cell proliferation in vitro. Oncotarget,2017,8:15704-15715.
|
| [7] |
Giannini E,Risso D,Botta F,et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med,2003,163:218-224.
|
| [8] |
Yang HI,Yuen MF,Chan HL,et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B):development and validation of a predictive score. Lancet Oncol,2011,12:568-574.
|
